Supernus Receives Final FDA Approval for Trokendi XR® for Migraine Prophylaxis in Adults and Adolescents
Based on IMS prescription data, Topiramate is the most prescribed drug for the treatment of migraine prophylaxis with more than 9 million prescriptions annually. This represents approximately 50% of all IMS prescriptions written for migraine prophylaxis.
"This approval and our imminent launch in migraine represent an opportunity for Supernus to further strengthen its leadership position in this market with Trokendi XR," stated
About Trokendi XR
Trokendi XR is a novel once-daily extended release formulation of topiramate for the treatment of epilepsy, and migraine prophylaxis. Trokendi XR is indicated for the prophylaxis of migraine headache in adults and adolescents 12 years of age and older, initial monotherapy in patients 6 years of age and older with partial onset or primary generalized tonic-clonic seizures; adjunctive therapy in patients 6 years of age and older with partial onset or primary generalized tonic-clonic seizures; and adjunctive therapy in patients 6 years of age and older with seizures associated with Lennox-Gastaut syndrome. The product is available in 25mg, 50mg, 100mg and 200mg extended-release capsules.
For current full prescribing and safety information, click here.
Forward Looking Statements
This press release contains forward-looking statements regarding the Company's ability to market Trokendi XR® in the migraine market. Actual results may differ materially from those in these forward-looking statements as a result of various factors, including, but not limited to, the ability of the Company to increase the number of prescriptions written for each of its products and the Company's ability to increase its net revenue. For a further description of these and other risks facing the Company, please see the risk factors described in the Company's 2016 Annual Report Form 10-K that was filed with the
Jack A. Khattar, President and CEO Gregory S. Patrick, Vice President and CFO Supernus Pharmaceuticals, Inc.301-838-2591 Or Investor Contact: Peter Vozzo Westwicke PartnersOffice: (443) 213-0505 Mobile: (443) 377-4767 Email: email@example.com
News Provided by Acquire Media